TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2305995
Drug: TTFCA 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 60 mg tid (Group D, normal subjects)
Study: 2305995
Drug: TTFCA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA (both doses in Groups A and B)
Study: 7000223
Drug: Intramuscular cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular cephradine 1 g 6-hourly for 48 hours
Study: 28476133
Drug: Palatal brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palatal brushing and standard oral and denture hygiene measures
Study: 28476133
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral and denture hygiene measures
Study: 23786948
Drug: Structured lipid
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured lipid emulsion as parenteral alimentation
Study: 23786948
Drug: Physically mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physically mixed medium and long‐chain fat emulsion as parenteral alimentation
Study: 19771403
Drug: 25U BoNT/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25U BoNT/A diluted in 2.5 ml sodium chloride solution (group I)
Study: 19771403
Drug: 25U BoNT/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25U BoNT/A diluted in 4 ml sodium chloride solution (group II)
Study: 12770656
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with hyperbaric bupivacaine 1.5 mL 0.5%
Study: 12770656
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with a 50‐mL mixture containing 10 mL bupivacaine 0.5%, 10 mL prilocaine HCl 2%, and 30 mL isotonic solution with 1:200,000 epinephrine in combination with intravenous midazolam sedation
Study: 8935302
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg, daily)
Study: 8935302
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg, daily)
Study: 8935302
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg, daily)
Study: 29606135
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution with 20 mL/kg over 60 min at start of ERCP, followed by 3 mL/kg/h for 8 h thereafter
Study: 29606135
Drug: No fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluids or normal saline with a maximum of 1.5 mL/kg/h and 3 L/24 h
Study: 26902403
Drug: Anti-resorptive (AR)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-resorptive (AR) combination of pomegranate fruit and grape seed extracts
Study: 26902403
Drug: Bone formation
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone formation (BF) combination of quercetin and licorice extracts
Study: 26902403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all four plant extracts (AR plus BF)
Study: 16675182
Drug: Right hip-flexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right hip-flexed left lateral position (L)
Study: 8744
Drug: Physostigmine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (intravenous administration)
Study: 30948503
Drug: Tangminling pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangminling pill
Study: 20012446
Drug: Alcohol beverage
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol beverage (1 g of ethanol per kg bodyweight; vodka and orange juice)
Study: 15801939
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg bid for 7 days
Study: 12566365
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg BID
Study: 12566365
Drug: AGI‐1067 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI‐1067 70 mg once daily
Study: 12566365
Drug: AGI‐1067 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI‐1067 140 mg once daily
Study: 12566365
Drug: AGI‐1067 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI‐1067 280 mg once daily
Study: 8374931
Drug: sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (320 mg/day)
Study: 3534803
Drug: DHE 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE 0.5 mg plus heparin 5000 U
Study: 3534803
Drug: DHE 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE 0.5 mg plus heparin 2500 U
Study: 3534803
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 U
Study: 3534803
Drug: DHE 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE 0.5 mg
Study: 27181342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ananas comosus extract and honey (Bromelin®)
Study: 8101584
Drug: Morphine in
Normalized name: morphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine in 5% dextrose (100 micrograms/kg per h for 2 h followed by 25 micrograms/kg per h continuous infusion)
Study: 20630656
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and placebo
Study: 2943812
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0 and 1 month (Group I)
Study: 2943812
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0, 1 and 6 months (Group II)
Study: 2943812
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 10 micrograms of plasma‐derived hepatitis B vaccine (H‐B‐VAX) (Group III)
Study: 22587925
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion at 18 U×kg(‐1)×h(‐1) for 24 hours (Group A)
Study: 22587925
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 12,500 U of heparin once a day (Group B)
Study: 22587925
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin calcium injection twice a day (Group C)
Study: 18320208
Drug: Maltodextrin plus
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin plus hydrolyzed whey protein enriched with 175 mg of glutamine dipeptide (MGln)
Study: 12733728
Drug: Gross motor
Normalized name: Ostericum grosseserratum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gross motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Study: 12733728
Drug: Fine motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Study: 12733728
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/day)
Study: 1748336
Drug: Alfentanil, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil, up to 0.025 mg/kg
Study: 1748336
Drug: Fentanyl, 0.0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, 0.0025 mg/kg
Study: 7019841
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at eight-hour intervals in phase 2)
Study: 7019841
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at 24-hour intervals in phase 1)
Study: 7019841
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment (phase 2)
Study: 24502311
Drug: 2% methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% methylene blue aqueous solution irradiated with light emission diode device (MBLED/PDT) with 18 J/cm(2) and placebo capsule per week
Study: 24502311
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral fluconazole per week and placebo PDT (haematoxylin-diluted 1:10)
Study: 18036291
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (initial rate 50 microg.kg(‐1).min(‐1) increasing to 150 microg.kg(‐1).min(‐1) over 10 minutes)
Study: 14758947
Drug: Scheduled regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled regimen of minor oral analgesic medications (acetaminophen [10 mg/kg] and ibuprofen [10 mg/kg] alternating every 2 hours)
Study: 14758947
Drug: Analgesic medication
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medication when requested (Control Group B)
Study: 14758947
Drug: Scheduled regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled regimen of minor oral analgesic medications
Study: 11453909
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (allergen‐impermeable mattress encasing, acaricide spray containing tannic acid and benzylbenzoate)
Study: 11453909
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (allergen‐permeable encasing, spray containing water and traces of ethanol)
Study: 8111718
Drug: DTIC 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 650 mg/m2
Study: 8111718
Drug: DTIC 850
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 850 mg/m2
Study: 8111718
Drug: DTIC (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (combined low and high doses)
Study: 3183054
Drug: Pentazocine with
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine with low-dose naloxone
Study: 3183054
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with low-dose naloxone
Study: 30755164
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (11.4 mg betamethasone)
Study: 30755164
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose (placebo)
Study: 28672376
Drug: Phoneme Factory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phoneme Factory Sound Sorter software administered by educators over 9 weeks
Study: 25326216
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle treatment (group A)
Study: 25326216
Drug: Two cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycle treatment (group B)
Study: 24121100
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (12 weekly group sessions)
Study: 14501608
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg E2 + 25 g SPI with 120 mg isoflavones
Study: 14501608
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg E2 + 25 g SPI with 120 mg isoflavones
Study: 14501608
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg E2 + placebo
Study: 14501608
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg E2 + placebo
Study: 3547879
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine
Study: 11103750
Drug: Bioavailability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailability of cyclosporine
Study: 8730315
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (100 mg single dose on day 1 followed by 50 mg twice daily for 5 days)
Study: 8730315
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin (500 mg single dose on day 1 followed by 250 mg twice daily for 4 days and another 500 mg single dose on day 6)
Study: 26688463
Drug: Oral herbs
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral herbs (n=35)
Study: 26688463
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=32)
Study: 26688463
Drug: Post-salvage therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-salvage therapy comparison
Study: 15892437
Drug: 3-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug regimen of indinavir + zidovudine (or stavudine) + lamivudine
Study: 15892437
Drug: 2-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug combination of zidovudine (or stavudine) + lamivudine
Study: 10562783
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with continuous epidural bupivacaine 15 mg h‐1 or bupivacaine 10 mg h‐1 with epidural morphine 0.2 mg h‐1
Study: 8721469
Drug: DMSO 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO 50% in a fatty cream (group A)
Study: 6841664
Drug: Loprazolam (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam (0.5, 1.0, and 1.5 mg)
Study: 6841664
Drug: Midazolam (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (10, 20, and 30 mg)
Study: 26189570
Drug: Intramuscular paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular paliperidone palmitate 3-month (PP3M) formulation (75-525 mg eq)
Study: 26189570
Drug: Intramuscular paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular paliperidone immediate release (IR) (1 mg)
Study: 24263659
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of L-carnitine (LK-3)
Study: 24263659
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of L-carnitine (LK-4)
Study: 16714323
Drug: Psilocybin (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (medium dose: 115 microg/kg)
Study: 16714323
Drug: Psilocybin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (high dose: 250 microg/kg)
Study: 16714323
Drug: Psilocybin (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (medium and high doses)
Study: 15288990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol and dolasetron
Study: 7714223
Drug: MDL 11,939,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 11,939, 32 mg thrice daily
Study: 2496225
Drug: Encainide during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide during chronic treatment with low dose quinidine (50 mg q 6 hr)
Study: 152681
Drug: Spironolactone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 200 mg daily
Study: 26541328
Drug: PC-enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-enriched virgin olive oil containing a mixture of 500 mg PC/kg from OO and thyme (FVOOT)
Study: 26541328
Drug: PC-enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-enriched virgin olive oil containing 500 mg PC/kg from OO (FVOO)
Study: 26541328
Drug: Virgin olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin olive oil naturally containing 80 mg PC/kg (VOO)
Study: 26349830
Drug: Meropenem (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (2 g) and RPX7009 (2 g) administered every 8 h as a 3-h intravenous infusion for a total of three doses
Study: 16758046
Drug: Terazosin 10
Normalized name: terazosin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 10 mg daily and analgesic (indomethacin) for a maximum of 4 weeks
Study: 16758046
Drug: Analgesic only
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic only (control group)
Study: 31762185
Drug: Leopold's maneuvers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leopold's maneuvers administered in the 28th week of pregnancy and re-administered in the 32nd and 36th weeks.
Study: 28575286
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IIV) during pregnancy
Study: 22311006
Drug: Welding fumes
Normalized name: Aluminum welding fumes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Welding fumes exposure at 1 mg/m(3) for 6 hours
Study: 22311006
Drug: Welding fumes
Normalized name: Aluminum welding fumes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Welding fumes exposure at 2.5 mg/m(3) for 6 hours
Study: 22311006
Drug: Ambient air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient air exposure (0 mg/m(3)) for 6 hours
Study: 18359422
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving new antibiotics during the surveillance period
Study: 18359422
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not on antibiotics
Study: 18359422
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on no new antibiotics
Study: 18359422
Drug: Potential antibiotic
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential antibiotic error rates
Study: 11716192
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2.5 mg, i.e., 100,000 IU) administered orally at three specific periods (end of September, November, and January)
Study: 11716192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin D3 treatment)
Study: 8424419
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg over 20 min)
Study: 2434546
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17-propionate cream applied twice daily for 1 week
Study: 18412782
Drug: Dry tablet
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry tablet insertion of vaginal misoprostol (400 microg)
Study: 18412782
Drug: Gel form
Normalized name: Timoptic-XE 0.5 % Gel Forming Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel form of vaginal misoprostol (400 microg)
Study: 12377965
Drug: 2-hour daily
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour daily infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm A)
Study: 12377965
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm B)
Study: 12377965
Drug: Toxicity incidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity incidence between treatment arms
Study: 10085671
Drug: Oral Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Granisetron 1 mg
Study: 30272231
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg) once daily for 14 days
Study: 30272231
Drug: Darunavir/cobicistat (800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/cobicistat (800/150 mg) once daily for 14 days
Study: 30272231
Drug: Dolutegravir/darunavir/cobicistat (DTG/DRV/COBI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir/darunavir/cobicistat (DTG/DRV/COBI) once daily
Study: 21394686
Drug: Transgingival antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgingival antibacterial photodynamic therapy (PDT)
Study: 21394686
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site rinsed with ringer solution
Study: 17031264
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole 200 mg twice daily for 24 weeks
Study: 12974986
Drug: Nemifitide (re-treatment)
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nemifitide (re-treatment)
Study: 12974986
Drug: Nemifitide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemifitide (initial treatment)
Study: 22661752
Drug: i.v. MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. MgSO(4) at a dose of 50 mg kg(‐1) diluted in 100 ml 0.9% saline solution followed by 15 mg kg(‐1) h(‐1) for 6 h
Study: 22661752
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at the same volume [mean (sd) 64 (10) ml]
Study: 10801253
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg daily for 6 months
Study: 30843231
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (no PDL treatment)
Study: 12087350
Drug: S21402 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: S21402 (250 mg)
Study: 7872387
Drug: Topical fibronectin
Normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fibronectin ophthalmic solution (3.5 mg/ml)